Gilead v Merck hepatitis C dispute rocked by new allegation

A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Merck to pay Gilead $14m in attorneys’ fees

20 July 2017 A California district court has awarded Gilead Sciences $13.8 million in attorneys’ fees in a patent dispute against Merck & Co, Merck Sharp & Dohme and Isis Pharmaceuticals.

Americas

Judge overturns $200m award in Gilead v Merck

9 June 2016 A US court has overturned an earlier ruling in which Merck was awarded $200 million in damages for patent infringement after finding that the pharmaceutical company had engaged in misconduct.

Americas

Merck handed $200m in Gilead hepatitis C row

29 March 2016 Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Gilead v Merck hepatitis C dispute rocked by new allegation

More on this story

Editor's picks

Editor's picks

More features